Cómo citar
1.
Opromolla DVA. A proibição da talidomida no eritema nodoso hansênico. Hansen. Int. [Internet]. 30 de noviembre de 2000 [citado 23 de noviembre de 2024];25(2):111-2. Disponible en: https://periodicos.saude.sp.gov.br/hansenologia/article/view/36432
Resumen
.
Citas
1 . BA RBA RUBIO, J ; FRANCO GONZA LE Z, E L u p u s eritematosos discoide y talidomida. Dermatologia - Rev. Mex., v.19, p.131, 1975.
2. BARNHILL, R.L.; McDOUGALL, A.C. Thalidomide: use and possible mode of action in reactional lepromatous leprosy and in various other conditions. J. Amer. Acad. DermatoL, v.7, p.317-323, 1982.
3. GRINSPAN, D. Significant response of oral aphthosis to thalidomide treatment. J. Amer. Acad. DermatoL, v.12, p.85-90, 1985.
4. GROSSHANS, E.; ILLY, G. Thalidomide therapy for inflammatory dermatoses. Int. J. DermatoL, v.23, p.598602, 1984.
5. HASPER, M. Chronic cutaneous lupus erythematosus: thalidomide treatment of 11 patients. Arch. DermatoL, v.119, p.812-815, 1983.
6. MARWICK, C. A talidomida está de volta - sob rígido controle. JAMA, v.2, n.2, p.290, 1998.
7. PENNA, GO, PINHEIRO, A.M.C., HAJJAR, L.A. Talidomida: mecanismo de ação, efeitos colaterais e uso terapêutico. An. bras. Dermatol., v.73, n.6, p.501-514, 1998.
8. PROENÇA, N.G. Emprego de talidomida em dermatologia. An. bras. DermatoL, v.70, n.1, p.61-67, 1995.
9. RUSTIN, M.H.A.; GILKES, J.J.H.; ROBINSON, T.W.E. Pyoderma gangrenosum associated with Behçet's disease: treatment with thalidomide. J. Amer. Acad. DermatoL, v.23, p.941-943, 1990.
10. SHESKIN, J. Thalidomide in the treatment of lepra reactions. Clin. PharmacoL Ther., v.6, p.303, 1965.
11. THOMPSON, C. Thalidomide effective for AIDS related oral ulcers (news). Lancet, v.346, p.1289, 1995.
12. VAN DEN BROECK, H. Treatment of prurigo nodularis with thalidomide. Arch. Dermatol, v.116, p.571-572, 1980
2. BARNHILL, R.L.; McDOUGALL, A.C. Thalidomide: use and possible mode of action in reactional lepromatous leprosy and in various other conditions. J. Amer. Acad. DermatoL, v.7, p.317-323, 1982.
3. GRINSPAN, D. Significant response of oral aphthosis to thalidomide treatment. J. Amer. Acad. DermatoL, v.12, p.85-90, 1985.
4. GROSSHANS, E.; ILLY, G. Thalidomide therapy for inflammatory dermatoses. Int. J. DermatoL, v.23, p.598602, 1984.
5. HASPER, M. Chronic cutaneous lupus erythematosus: thalidomide treatment of 11 patients. Arch. DermatoL, v.119, p.812-815, 1983.
6. MARWICK, C. A talidomida está de volta - sob rígido controle. JAMA, v.2, n.2, p.290, 1998.
7. PENNA, GO, PINHEIRO, A.M.C., HAJJAR, L.A. Talidomida: mecanismo de ação, efeitos colaterais e uso terapêutico. An. bras. Dermatol., v.73, n.6, p.501-514, 1998.
8. PROENÇA, N.G. Emprego de talidomida em dermatologia. An. bras. DermatoL, v.70, n.1, p.61-67, 1995.
9. RUSTIN, M.H.A.; GILKES, J.J.H.; ROBINSON, T.W.E. Pyoderma gangrenosum associated with Behçet's disease: treatment with thalidomide. J. Amer. Acad. DermatoL, v.23, p.941-943, 1990.
10. SHESKIN, J. Thalidomide in the treatment of lepra reactions. Clin. PharmacoL Ther., v.6, p.303, 1965.
11. THOMPSON, C. Thalidomide effective for AIDS related oral ulcers (news). Lancet, v.346, p.1289, 1995.
12. VAN DEN BROECK, H. Treatment of prurigo nodularis with thalidomide. Arch. Dermatol, v.116, p.571-572, 1980
Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.
Descargas
Los datos de descargas todavía no están disponibles.
